WuXi XDC Cayman (HKSE:02268) Debt-to-Equity : 0.00 (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Debt-to-Equity?

WuXi XDC Cayman's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$3 Mil. WuXi XDC Cayman's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$3 Mil. WuXi XDC Cayman's Total Stockholders Equity for the quarter that ended in Jun. 2023 was HK$1,858 Mil. WuXi XDC Cayman's debt to equity for the quarter that ended in Jun. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for WuXi XDC Cayman's Debt-to-Equity or its related term are showing as below:

During the past 4 years, the highest Debt-to-Equity Ratio of WuXi XDC Cayman was 1.18. The lowest was 0.00. And the median was 0.05.

HKSE:02268's Debt-to-Equity is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 0.22
* Ranked among companies with meaningful Debt-to-Equity only.

WuXi XDC Cayman Debt-to-Equity Historical Data

The historical data trend for WuXi XDC Cayman's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Debt-to-Equity Chart

WuXi XDC Cayman Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

1.18

0.05

WuXi XDC Cayman Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			N/A	0.05	0.02	-	-

Competitive Comparison of WuXi XDC Cayman's Debt-to-Equity

For the Diagnostics & Research subindustry, WuXi XDC Cayman's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi XDC Cayman's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's Debt-to-Equity falls into.

WuXi XDC Cayman Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

WuXi XDC Cayman's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.364	+	1.745)	/	5965.816
	=	0.00

WuXi XDC Cayman's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.093	+	2.709)	/	1857.919
	=	0.00

WuXi XDC Cayman (HKSE:02268) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

WuXi XDC Cayman Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi XDC Cayman (HKSE:02268) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

L74:Germany

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN

Website

WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (HKSE:02268) Headlines

No Headlines